User profiles for "author:Jeffrey Enejosa"
 | Jeffrey Enejosa, MDVerified email at abbvie.com Cited by 4999 |
[HTML][HTML] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant, E DeJesus, JR Arribas… - … England Journal of …, 2006 - Mass Medical Soc
Background Durable suppression of replication of the human immunodeficiency virus (HIV)
depends on the use of potent, well-tolerated antiretroviral regimens to which patients can …
depends on the use of potent, well-tolerated antiretroviral regimens to which patients can …
[HTML][HTML] ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients …
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir,
ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and …
ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and …
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
SB Cohen, RF Van Vollenhoven, KL Winthrop… - Annals of the …, 2021 - ard.bmj.com
Objectives This integrated analysis presents the safety profile of upadacitinib, a Janus
kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely …
kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely …
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
JR Arribas, AL Pozniak, JE Gallant… - JAIDS Journal of …, 2008 - journals.lww.com
Background: As antiretroviral regimens for the treatment of HIV infection improve, trials
providing data on long-term follow-up are increasingly important. Methods: A regimen of …
providing data on long-term follow-up are increasingly important. Methods: A regimen of …
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic …
AL Pozniak, JE Gallant, E DeJesus… - JAIDS Journal of …, 2006 - journals.lww.com
Background: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF),
emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with …
emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with …
[HTML][HTML] Upadacitinib in rheumatoid arthritis: a benefit–risk assessment across a phase III program
PG Conaghan, E Mysler, Y Tanaka… - Drug Safety, 2021 - Springer
Treating to a target of clinical remission or low disease activity is an important principle for
managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying …
managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying …
[HTML][HTML] Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis
Background & Aims We evaluated the efficacy and safety of upadacitinib, an oral selective
inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC). Methods We …
inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC). Methods We …
[HTML][HTML] Trial of upadacitinib or abatacept in rheumatoid arthritis
A Rubbert-Roth, J Enejosa, AL Pangan… - … England Journal of …, 2020 - Mass Medical Soc
Background Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid
arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell …
arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell …
The safety and efficacy of tenofovir df in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1—infected patients
I Cassetti, JVR Madruga, JMAH Suleiman, A Etzel… - HIV clinical …, 2007 - Taylor & Francis
Background: Study 903 is a phase 3 trial with a completed 144-week, double-blind phase
comparing tenofovir DF (TDF) to stavudine (d4T) in combination with lamivudine (3TC) and …
comparing tenofovir DF (TDF) to stavudine (d4T) in combination with lamivudine (3TC) and …
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in …
RM Fleischmann, MC Genovese, JV Enejosa… - Annals of the …, 2019 - ard.bmj.com
Background In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg
once daily was superior to placebo or adalimumab on background methotrexate (MTX) for …
once daily was superior to placebo or adalimumab on background methotrexate (MTX) for …